Surgery of basal cell carcinoma around the lacrimal canaliculus can be necessary after primary treatment with intralesional interferon alpha 2b [7]

Indian Journal of Ophthalmology

Volumn 56, Issue 1, 2008, Pages 85-86

  Huerva, V ^a   Mangues, I ^a  

^a HOSPITAL ARNAU DE VILANOVA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 38149030324     PISSN: 03014738     EISSN: 03014738     Source Type: Journal    
DOI: 10.4103/0301-4738.37590     Document Type: Letter

References (4)

1. Cook BE Jr, Bartley GB. Epidemiologic characteristics and clinical course of patients with malignant eyelid tumors in an incidence cohort in Olmstead County, Minesota. Ophthalmology 1999;106:746-50.
2. Fenton S, Kennedy S, Moriarty P. The role of interferon alpha 2b as an adjunctive treatment in the management of aggressive basal cell carcinoma of the eyelids. Acta Ophthalmol Scand 2002;80:674-5.
3. Greenway HT, Cornell RC, Tanner DJ, Peets E, Bordin GM, Nagi C. Treatment of basal cell carcinoma with intralesional interferon. J Am Acad Dermatol 1986;15:437-43.
4. Chimenti S, Peris K, Di Cristofaro S, Fargnoli MC, Torlone G. Use of recombinant interferon alpha-2b in the treatment of basal cell carcinoma. Dermatology 1995;190:214-7.